Odyssey Just Raised $304M Before Most Biotechs Finish Their Slide Decks

Behind OD-07656 sits a bench of five preclinical programs targeting lupus, atopic dermatitis, asthma, COPD, and other inflammatory conditions. None of those are in human trials yet. They're the farm team; OD-07656 is the starter on the mound.

That matters, because investors are essentially betting $304 million on a single mid-stage clinical readout, plus a platform they believe can keep producing candidates. It's a big bet on potential.

Why TPG's Side Deal Says More Than the IPO Itself

The $25 million private placement from TPG might look small next to the $279 million IPO. But in biotech signaling, it's enormous.

TPG Life Sciences Innovations was already an Odyssey shareholder from the Series D round. When an existing investor buys more shares at the IPO price (no discount, no special terms), it tells every other investor in the room: "We've seen the data up close, and we're doubling down."

Contrast that with the typical IPO playbook, where early investors are often looking to sell shares and lock in gains. TPG did the opposite. That kind of move can stabilize a stock in its early public trading days and signals alignment between insiders and new public shareholders.

The 2026 IPO Window Is Open (For the Right Companies)

Odyssey didn't price this deal in a vacuum. The biotech IPO market is having its best stretch since 2021, though "best" comes with an asterisk.

Only 8 U.S. biotech IPOs happened in all of 2025, the lowest in years. But quality has replaced quantity in 2026. First-quarter biotech IPOs raised $1.7 billion in aggregate, the highest quarterly total in five years. The median deal size hit roughly $287.5 million, more than double what it was in early 2025.

The pattern is unmistakable: fewer deals, much bigger checks. Eikon Therapeutics priced a $381 million offering. Aktis Oncology upsized to $318 million. Veradermics pulled in $256 million. Industry watchers expect around 30 to 35 biotech IPOs this year, a modest recovery from 2025's drought but nowhere near the 2021 frenzy.

The catch? The window is open almost exclusively for later-stage companies with real clinical data. No preclinical biotech has gone public since 2024. Investors aren't buying dreams anymore; they're buying de-risked stories with clear catalysts. Odyssey, with its Phase 2 trial already running and $700 million in prior funding, fit the mold perfectly.

The Risks Nobody's Whispering About

The underwriters on this deal (J.P. Morgan, TD Cowen, and Cantor) are under a quiet period until mid-June, so we won't see formal analyst ratings for a couple of weeks. But the risks are straightforward.

Odyssey's entire near-term story rides on one drug in one mid-stage trial. If OD-07656 misses in ulcerative colitis, the stock could compress fast. There's no backup clinical asset to cushion the blow. The preclinical programs are interesting on paper, but they're years away from generating the kind of data that moves a stock price.

One pre-pricing analyst commentary called the valuation (originally implied around $810 million) "not cheap" for a single clinical asset plus five preclinical programs in a crowded indication. The final deal priced even bigger than that initial target, so the bar for clinical success just got higher.

The Bottom Line

Odyssey Therapeutics pulled off one of the cleanest biotech IPOs in years: upsized, priced at the top of the range, and backed by a $25 million anchor from an existing investor who could have simply cashed out instead.

With roughly $304 million in fresh capital on top of $700 million raised privately, the company has a multi-year runway to push OD-07656 through later-stage trials without scrambling for more money. That financial cushion is rare in biotech, where cash crunches kill good science all the time.

But all of that firepower points toward a single Phase 2 readout. It's a high-conviction bet on one mechanism, one indication, one dataset. If the data delivers, Odyssey could become a defining name in autoimmune medicine. If it doesn't, $304 million buys a lot of runway to figure out Plan B, though investors paying $18 a share might not be thrilled about the detour.

For the broader biotech IPO market, the message is clear: the window is open, the checks are big, and Wall Street has an appetite again. Just make sure you bring the goods.

One Shot to Silence a Gene Forever

Intellia just delivered the first successful Phase 3 trial for an in vivo CRISPR therapy, cutting hereditary angioedema attacks by 87% with a single infusion. The results could reshape how we think about treating genetic diseases forever.